Brett Sandercock - 10 Nov 2021 Form 4 Insider Report for RESMED INC (RMD)

Role
Chief Financial Officer
Signature
Brett Sandercock, Chief Financial Officer
Issuer symbol
RMD
Transactions as of
10 Nov 2021
Net transactions value
-$507,050
Form type
4
Filing time
12 Nov 2021, 12:17:49 UTC
Previous filing
12 Oct 2021
Next filing
18 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $144,400 +2,500 +2.9% $57.76 87,333 10 Nov 2021 Direct F1
transaction RMD ResMed Common Stock Sale $651,450 -2,500 -2.9% $260.58 84,833 10 Nov 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -2,500 -10% $0.000000 22,500 10 Nov 2021 ResMed Common Stock 2,500 $57.76 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was conducted under a Rule 10b5-1 plan.
F2 Includes 46.9876 shares of ResMed stock purchased on October 29, 2021, through the ResMed Employee Stock Purchase Plan.
F3 Represents date options first became exercisable. Options vest 1/3 per year.